biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Sep 24, 2018 1:56pm

96 Views

Post# 28678922

RE:BrearDown

Well, Amarin (Vascepa) and Astrazeneca (Epanova) have had their products approved for treatement of severe hypertriglyceridemia (>500 mg/dL) for 6 and 4 years now, respectively. Vascepa REDUCE-IT cardiovascular outcomes trial (CVOT) had positive readout today for cardioprotective effects in patients with mild hypertriglyceridemia (150-500 mg/dL). Epanova STRENGTH CVOT reads out next year in a similar patient population. Acasti's CaPre product is still in Phase 3 (two TRILOGY trials) safety/efficacy for TG lowering in patients with severe hypertriglyceridemia (500-1500 mg/dL), has yet to run a Phase 3 for mild hypertriglyceridemia and has yet to start a CVOT. Acasti could be a good addition to the available products, but has a ways to go for clinical development. TRILOGY doesn't wrap up until 2019 and if they do submit NDA/MMA based off of this trial it will only be for TG lowering in severe hypertriglyceridemia w/o any CVOT data.

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale